Preterm BirthPhase 4ALECNCT05132829
Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial
A Phase 4 study testing Azithromycin 1 gram IV and Cefazolin and indomethacin in people with Preterm Birth and Obstetric Labor, Premature, run by Thomas Jefferson University at 2 sites in United States.
Trial summary
Azithromycin is an antibiotic that is effective against bacteria that been associated with preterm birth (PTB). The purpose of this study is to evaluate if the addition of azithromycin prior to exam indicated cerclage prolongs gestation. A cerclage is a suture placed in the cervix to prolong gestation. Read more about this study
- Who is it for?
- Ages 18 to 80 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Preterm Birth, Obstetric Labor, Premature, Obstetric Labor Complications
- What is being tested?
- Azithromycin 1 gram IV and Cefazolin and indomethacin
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 2 sitesUnited States
- Study dates
- 20 Dec 2021to Jun 2025
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Pregnant women with singleton pregnancies
- ≥18 years old
- Estimated gestational age less than 24 weeks
- Meet criteria for an exam indicated cerclage
- Patients must also be able to provide consent, demonstrate an understanding of the purpose of the study, and agree to the study protocol.
Who cannot join
- Human immunodeficiency virus (HIV) positive status
- Known prolonged QT syndrome
- Major fetal congenital anomalies
- Temperature of 100.4 F or higher
- Prior cerclage during the current pregnancy
- Contraindication to indomethacin
- Allergy to both penicillin and clindamycin
- Received indomethacin or any antibiotics within 7 days before their presentation
Trial locations and contacts
2 sites in 1 country.
United States2 sites, 2 recruiting
- Recruiting
Northwestern University
Chicago, Illinois, 60611
Emily Miller, MD
- Recruiting
Rutgers Robert Wood Johnson
New Brunswick, New Jersey, 08901
Justin Brandt, MD
About this study
Official title: Azithromycin to Improve Latency in Exam Indicated Cerclage: a Randomized Control Trial
Azithromycin is an antibiotic that is effective against bacteria that been associated with preterm birth (PTB). The purpose of this study is to evaluate if the addition of azithromycin prior to exam indicated cerclage prolongs gestation. A cerclage is a suture placed in the cervix to prolong gestation.
Read the detailed description
Preterm birth (PTB) continues to be a leading cause of neonatal morbidity and mortality. The rate of spontaneous PTB (delivery before 37 weeks gestation) is one in ten pregnancies and a history of prior preterm birth remains a risk factor for recurrence. The pathophysiology of cervical insufficiency leading to PTB remains poorly understood.
While interventions for PTB prevention are limited, the American College of Obstetrics and Gynecology (ACOG) supports the use of cervical cerclage. A physical exam indicated cerclage may be placed in the setting of painless cervical dilation in the second trimester. The cerclage is believed to provide mechanical support to a weakened cervix and promote the cervical mucosal plug as a barrier to ascending infection.
While many aspects of cerclage use have been extensively studied, the use of antibiotics prior to placement remains under evaluated. While antibiotic use is recommended during cesarean section, preterm premature rupture of membranes (PPROM), and obstetric anal sphincter injuries (OASIS), ACOG currently does not recommend perioperative antibiotics or prophylactic tocolytics at the time of cerclage placement citing insufficient evidence.
Miller et al. performed a randomized controlled trial (RCT) showing an increased incidence of pregnancy prolongation by at least 28 days among women who received indomethacin and perioperative antibiotics in the setting of an exam indicated cerclage compared to those who received no perioperative medications (92.3% vs 62.5%, p=0.01). Participants in the experimental arm received cefazolin or clindamycin if they had a penicillin allergy. Cefazolin is a first generation cephalosporin that has activity against gram positive cocci and gram negative rods and is commonly used for surgical prophylaxis. Clindamycin is a protein synthesis inhibitor and covers gram positive organisms and anaerobic bacteria, making it an appropriate alternative in cases of penicillin allergy. The use of cefazolin specifically with indomethacin has been studied retrospectively and showed a significant improvement in gestational latency (adjusted relative risk [aRR] 1.21, 95% CI 1.05-1.40) and birth weight (+489.8 grams, 95% CI 64.6-915.0).
The use of prolonged azithromycin with cerclage has been studied in a prospective, non- randomized fashion. In this study, patients were given 500mg azithromycin for 3 days and this was repeated every 10 days until 34 weeks. Patients who received this regimen and a cerclage had lower PTB (65.7% vs 5.7%, p<0.001) and reduced immediate fetal mortality (37.1% vs 0%, p<0.001).
The aim of our study is to determine if the addition of azithromycin prior to exam indicated cerclage prolongs gestation. Azithromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome and inhibits transpeptidation. It is effective against a wide variety of bacteria, specifically mycoplasma which has been associated with preterm birth. Azithromycin is currently used in obstetrics for patients undergoing nonelective cesarean delivery and as part of latency antibiotics in the setting of PPROM.
- Conditions
- Preterm Birth, Obstetric Labor, Premature, Obstetric Labor Complications, Pregnancy Complications, Physiological Effects of Drugs, Uterine Cervical Incompetence
- Being tested
- Azithromycin 1 gram IV, Cefazolin and indomethacin
- Keywords
- cerclage, preterm birth, premature cervical dilation, antibiotics
- Medical subject headings
- Premature Birth, Obstetric Labor, Premature, Obstetric Labor Complications, Pregnancy Complications, Uterine Cervical Incompetence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Azithromycin 1 gram IVDrug
Perioperative addition of azithromycin at the time of physical exam indicated cerclage placement.
Cefazolin and indomethacinDrug
Perioperative standard of care with cefazolin and indomethacin
| Study group | Role | What they receive |
|---|---|---|
| Cefazolin and Indomethacin | Other | Control arm- perioperative cefazolin and indomethacin Receives: Drug: Cefazolin and indomethacin |
| Azithromycin + control | Experimental | perioperative azithromycin, cefazolin and indomethacin Receives: Drug: Azithromycin 1 gram IV; Drug: Cefazolin and indomethacin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Gestational Latency Achieved Between Cerclage Placement and Time of Delivery
Mean gestational latency achieved Between Cerclage Placement and Time of Delivery
Measured: 24 weeks following cerclage placement
Secondary outcomes (7)
Preterm birth <37 weeks, <34 weeks, <32 weeks, <28 weeks, <24 weeks
Preterm delivery stratified by gestational age at delivery in weeks
Measured: at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
Mean gestational age at delivery
Measured in weeks
Measured: at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
chorioamnionitis
Histologic or clinical diagnosis
Measured: at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
birth weight
measured in grams
Measured: at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
Admission to neonatal intensive care unit
If admitted, measured in days
Measured: at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
Neonatal Morbidity and Mortality
including apgars, Respiratory Distress Syndrome, Bronchopulmonary dysplasia, Retinopathy of prematurity, Intraventricular hemorrhage (IVH) (grade 3 or 4), patent ductus arteriosus, and neonatal death
Measured: within 28 days of delivery
Cervicovaginal cytokine analysis
Measurement of proinflammatory cytokines in pg/ml (IL-1B, IL-2, IL-4, IL-6, IL-8, IL-8, IL-10, G-CSF, GM-CSF, MCP-1, TNF-a, IFN-g, CCL5, VEGF, ICAM-1) from cervicovaginal fluid at the time of cerclage placement and at follow up 1-4 weeks after placement
Measured: Cerclage placement and 1-4 weeks after
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Nov 2021
- Study start20 Dec 2021
- Primary completionDec 2024 (estimated)
- Study completionJun 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Preterm BirthStudies of the same condition, open and under way.
- More trials run by Thomas Jefferson UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Thomas Jefferson University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jenani S Jayakumaran, MD, Principal investigator, Thomas Jefferson UniversityRupsa Boelig, MD, Principal investigator, Thomas Jefferson University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05132829
- Sponsor's protocol ID
- 21D.746
- Acronym
- ALEC
- Status last verified
- Jun 2023
- First submitted
- 25 Oct 2021
- Last updated
- 26 Jun 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Jayakumaran JS, Khanuja K, Fischer SA, Miller ES, Rosenfeld EB, Brandt JS, Piacquadio M, Kalifeh A, Boelig RC. Azithromycin to improve latency in examination-indicated cerclage: a multicenter randomized controlled trial. Am J Obstet Gynecol MFM. 2026 Apr;8(4):101818. doi: 10.1016/j.ajogmf.2025.101818. Epub 2025 Oct 22.
PubMed 41135925
Study at a glance
From the registry record, last updated by the sponsor on 26 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Azithromycin to Improve Latency in Exam Indicated Cerclage: a Randomized Control Trial
- ClinicalTrials.gov ID
- NCT05132829
- Acronym / sponsor ID
- ALEC / 21D.746
- Conditions
- Preterm Birth, Obstetric Labor, Premature, Obstetric Labor Complications, Pregnancy Complications, Physiological Effects of Drugs, Uterine Cervical Incompetence
- Keywords
- cerclage, preterm birth, premature cervical dilation, antibiotics
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Thomas Jefferson UniversityUniversity, hospital or other
- Study start
- 20 Dec 2021 (actual)
- Primary completion
- Dec 2024 (estimated)
- Study completion
- Jun 2025 (estimated)
- First posted
- 24 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Azithromycin is an antibiotic that is effective against bacteria that been associated with preterm birth (PTB). The purpose of this study is to evaluate if the addition of azithromycin prior to exam indicated cerclage prolongs gestation. A cerclage is a suture placed in the cervix to prolong gestation.
Detailed description
Preterm birth (PTB) continues to be a leading cause of neonatal morbidity and mortality. The rate of spontaneous PTB (delivery before 37 weeks gestation) is one in ten pregnancies and a history of prior preterm birth remains a risk factor for recurrence. The pathophysiology of cervical insufficiency leading to PTB remains poorly understood.
While interventions for PTB prevention are limited, the American College of Obstetrics and Gynecology (ACOG) supports the use of cervical cerclage. A physical exam indicated cerclage may be placed in the setting of painless cervical dilation in the second trimester. The cerclage is believed to provide mechanical support to a weakened cervix and promote the cervical mucosal plug as a barrier to ascending infection.
While many aspects of cerclage use have been extensively studied, the use of antibiotics prior to placement remains under evaluated. While antibiotic use is recommended during cesarean section, preterm premature rupture of membranes (PPROM), and obstetric anal sphincter injuries (OASIS), ACOG currently does not recommend perioperative antibiotics or prophylactic tocolytics at the time of cerclage placement citing insufficient evidence.
Miller et al. performed a randomized controlled trial (RCT) showing an increased incidence of pregnancy prolongation by at least 28 days among women who received indomethacin and perioperative antibiotics in the setting of an exam indicated cerclage compared to those who received no perioperative medications (92.3% vs 62.5%, p=0.01). Participants in the experimental arm received cefazolin or clindamycin if they had a penicillin allergy. Cefazolin is a first generation cephalosporin that has activity against gram positive cocci and gram negative rods and is commonly used for surgical prophylaxis. Clindamycin is a protein synthesis inhibitor and covers gram positive organisms and anaerobic bacteria, making it an appropriate alternative in cases of penicillin allergy. The use of cefazolin specifically with indomethacin has been studied retrospectively and showed a significant improvement in gestational latency (adjusted relative risk [aRR] 1.21, 95% CI 1.05-1.40) and birth weight (+489.8 grams, 95% CI 64.6-915.0).
The use of prolonged azithromycin with cerclage has been studied in a prospective, non- randomized fashion. In this study, patients were given 500mg azithromycin for 3 days and this was repeated every 10 days until 34 weeks. Patients who received this regimen and a cerclage had lower PTB (65.7% vs 5.7%, p<0.001) and reduced immediate fetal mortality (37.1% vs 0%, p<0.001).
The aim of our study is to determine if the addition of azithromycin prior to exam indicated cerclage prolongs gestation. Azithromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome and inhibits transpeptidation. It is effective against a wide variety of bacteria, specifically mycoplasma which has been associated with preterm birth. Azithromycin is currently used in obstetrics for patients undergoing nonelective cesarean delivery and as part of latency antibiotics in the setting of PPROM.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cefazolin and Indomethacin | Other | Drug: Cefazolin and indomethacinControl arm- perioperative cefazolin and indomethacin |
| Azithromycin + control | Experimental | Drug: Azithromycin 1 gram IV, Drug: Cefazolin and indomethacinperioperative azithromycin, cefazolin and indomethacin |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Pregnant women with singleton pregnancies
- ≥18 years old
- Estimated gestational age less than 24 weeks
- Meet criteria for an exam indicated cerclage
- Patients must also be able to provide consent, demonstrate an understanding of the purpose of the study, and agree to the study protocol.
Key exclusion criteria (8 listed)
- Human immunodeficiency virus (HIV) positive status
- Known prolonged QT syndrome
- Major fetal congenital anomalies
- Temperature of 100.4 F or higher
- Prior cerclage during the current pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Azithromycin 1 gram IVPerioperative addition of azithromycin at the time of physical exam indicated cerclage placement. | Drug | Azithromycin + control |
| Cefazolin and indomethacinPerioperative standard of care with cefazolin and indomethacin | Drug | Azithromycin + control, Cefazolin and Indomethacin |
Primary outcome
Gestational Latency Achieved Between Cerclage Placement and Time of Delivery
Time frame: 24 weeks following cerclage placement
Mean gestational latency achieved Between Cerclage Placement and Time of Delivery
7 secondary outcomes
Preterm birth <37 weeks, <34 weeks, <32 weeks, <28 weeks, <24 weeks
Time frame: at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
Mean gestational age at delivery
Time frame: at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
chorioamnionitis
Time frame: at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
birth weight
Time frame: at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
Admission to neonatal intensive care unit
Time frame: at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.
Neonatal Morbidity and Mortality
Time frame: within 28 days of delivery
Cervicovaginal cytokine analysis
Time frame: Cerclage placement and 1-4 weeks after
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jun 2023.
- Derived from this study: PubMed 41135925Jayakumaran JS, Khanuja K, Fischer SA, Miller ES, Rosenfeld EB, Brandt JS, Piacquadio M, Kalifeh A, Boelig RC. Azithromycin to improve latency in examination-indicated cerclage: a multicenter randomized controlled trial. Am J Obstet Gynecol MFM. 2026 Apr;8(4):101818. doi: 10.1016/j.ajogmf.2025.101818. Epub 2025 Oct 22.
Related trials for Preterm Birth
Not yet recruitingPhase 1/2
Little Lungs Study
Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome
Recruiting
Effect of Support for Low-Income Mothers of Preterm Infants
Preterm Birth, Low; Birthweight, Extremely (999 Grams or Less)
Recruiting
Maximising Maternal Milk for Preterm Infant
Breastfeeding, Prematurity
Not yet recruitingObservational study
Probiotics in Preterm Babies Use & Abuse
Probiotic in Preterm Babies Use & Abuse, Uses
Recruiting
The Periviable GOALS Decision Support Tool
Pregnancy Preterm, Premature Birth
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jenani S Jayakumaran, MD principal investigator
Thomas Jefferson University
Rupsa Boelig, MD principal investigator
Thomas Jefferson University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Azithromycin 1 gram IV and Cefazolin and indomethacin in people with Preterm Birth and Obstetric Labor, Premature, run by Thomas Jefferson University at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 26 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Rupsa Boelig, MD (2159555000, Rupsa.boelig@jefferson.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gestational Latency Achieved Between Cerclage Placement and Time of Delivery (time frame: 24 weeks following cerclage placement). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05132829, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2023.